28.03.20: Not intended for U.S. and UK Media - Data from Phase III VICTORIA study presented at American College of Cardiology's 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)

Vericiguat significantly reduced the risk of the composite primary endpoint of cardiovascular death or heart failure hospitalizationVICTORIA is the first positive contemporary outcomes study focused exclusively on a chronic heart failure patient population following a worsening event / Treatment effect on the composite endpoint of cardiovascular death or heart failure hospitalization was consistently demonstrated regardless of background heart failure therapy / Vericiguat was well-tolerated - overall incidence rate of adverse events was comparable to placebo / Studied in a population with higher event rates than in other contemporary heart failure studies, the overall treatment benefit was driven by the patients within the lower three quartiles of baseline NT-proBNP levels, where relative risk reduction of the primary composite endpoint was up to 27%mehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news